DR. TAHLIA LEIGH YEO JIN WEIS PH.D., M.D.
Prescription History 1982967840
Surgery - Vascular Surgery in Marshfield, WI


Quality Rating: 100 out of 100 score

NPI Status: Active since June 16, 2012

Contact Information

1000 N OAK AVE
MARSHFIELD, WI
ZIP 54449
Phone: (715) 387-5511

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TAHLIA LEIGH YEO JIN WEIS PH.D., M.D., an active Vascular Surgery specialist practicing in Marshfield, WI. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 156 documented patient claims. Among these therapy options, the most frequently utilized medication is Clopidogrel, which accounts for 70 claims alone.

Medication Index

No matching medications currently found on file.

Atorvastatin Calcium

Generic Formulation: Atorvastatin CalciumSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 39
30-Day Fills 95.0
Days Supply 2,824
WI State Average Benchmarks
Peer Average Claims196.0
Peer Average 30-Day Fills491.2
Peer Average Days Supply14,607
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.1% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $388.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.96

State Avg Cost Per Claim

$12.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.

Therapeutic Applications

Atorvastatin is used along with a proper diet to help lower bad cholesterol and fats (such as LDL, triglycerides) and raise good cholesterol (HDL) in the blood. It belongs to a group of drugs known as statins. It works by reducing the amount of cholesterol made by the liver. Lowering bad cholesterol and triglycerides and raising good cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. In addition to eating a proper diet (such as a low-cholesterol/low-fat diet), other lifestyle changes that may help this medication work better include exercising, losing weight if overweight, and stopping smoking. Consult your doctor for more details.

Cilostazol

Generic Formulation: CilostazolSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 30
30-Day Fills 72.0
Days Supply 2,160
WI State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills48.6
Peer Average Days Supply1,437
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,318.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.96

State Avg Cost Per Claim

$37.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.

Therapeutic Applications

Cilostazol is used to improve the symptoms of a certain blood flow problem in the legs (intermittent claudication). Cilostazol can decrease the muscle pain/cramps that occur during exercise/walking. Claudication pain is caused by too little oxygen getting to the muscles. Cilostazol can increase blood flow and the amount of oxygen that gets to the muscles. Cilostazol is an antiplatelet drug and a vasodilator. It works by stopping blood cells called platelets from sticking together and prevents them from forming harmful clots. It also widens blood vessels in the legs. Cilostazol helps the blood to move more easily and keeps blood flowing smoothly in your body.

Clopidogrel

Generic Formulation: Clopidogrel BisulfateSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 70
30-Day Fills 193.3
Days Supply 5,774
WI State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills120.7
Peer Average Days Supply3,574
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.6% more claims than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $978.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.98

State Avg Cost Per Claim

$18.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.

Therapeutic Applications

Clopidogrel is used to prevent heart attacks and strokes in persons with heart disease (recent heart attack), recent stroke, or blood circulation disease (peripheral vascular disease). It is also used with aspirin to treat new/worsening chest pain (new heart attack, unstable angina) and to keep blood vessels open and prevent blood clots after certain procedures (such as cardiac stent). Clopidogrel works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It helps keep blood flowing smoothly in your body.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 17
30-Day Fills 25.0
Days Supply 750
WI State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills66.0
Peer Average Days Supply1,896
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.8% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,753.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$809.02

State Avg Cost Per Claim

$935.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. TAHLIA LEIGH YEO JIN WEIS PH.D., M.D. provides transparency into local medical care patterns within Marshfield, WI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Vascular Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.